Key result
Prior cancer linked to ~3.6-fold higher risk of newly diagnosed cancer after VTE.
Why the study?
VTE may be the earliest sign of cancer, but screening strategies for occult cancer are lacking partly due to limited data on the real-world incidence and risk factors of occult cancer after VTE diagnosis in the current era.
Observational (n=3,706)
Yes
In patients with acute symptomatic VTE without known active cancer, the 1-year incidence of newly-diagnosed cancer is 3.7% with continuous long-term risk, driven independently by older age, prior cancer history, autoimmune disorders, and unprovoked VTE.
May inform post-VTE risk stratification; leaves open whether targeted cancer screening improves outcomes.
Background/Introduction Venous thromboembolism (VTE) may be the earliest sign of cancer, although there are no established screening strategies for occult cancer. This could be partly due to lack of the real-world incidence and risk factors of occult cancer after diagnosis of VTE in the current era. Purpose The current study aimed to evaluate clinical characteristics and outcomes between patients who were newly diagnosed with cancer after diagnosis of VTE and those who were not, and investigate incidence and risk factors of newly-diagnosed cancer after diagnosis of VTE, using a large-scale multicenter observational database of patients with VTE. Methods The COMMAND VTE Registry-2 is a multicenter registry enrolling 5197 consecutive acute symptomatic VTE patients among 31 centers in Japan between January 2015 and August 2020. The current study population was consisted of 3706 patients without known active cancer at diagnosis of VTE, who were divided into patients with newly-diagnosed cancer after diagnosis of VTE (N=250, 6.7%) and those without (N=3456, 93.3%). To explore risk factors of newly-diagnosed cancer, we constructed the multivariable Cox proportional hazard model which consisted of variables with P values <0.05 in univariate analysis. Results The cumulative incidences of newly-diagnosed cancer were 1.5% at 30-day, 3.7% at 1-year, 7.0% at 3-year, 11.1% at 5-year, and 16.0% at 7-year. The most common types of newly-diagnosed cancer was colon (17.2%), followed by lung (14.8%) and blood (8.0%). Patients with newly-diagnosed cancer were older (71.6 vs. 67.2 years, P<0.001) and had lower body mass index (22.9 vs. 23.8 kg/m2, P=0.004) than those without. Patients with newly-diagnosed cancer more frequently had several comorbidities such as history of cancer (35% vs. 11%, P<0.001), hypertension (51% vs. 44%, P=0.04), diabetes mellitus (21% vs. 16%, P=0.03), and autoimmune disorder (20% vs. 13%, P=0.004), whereas they less frequently had transient provoking risk factors for VTE (29% vs. 39%, P<0.001). The cumulative incidence of all-cause death was significantly higher in patients with newly-diagnosed cancer than those without (59.3% vs. 21.0% at 7-year). The multivariable Cox proportional hazard model revealed that old age (hazard ratio [HR]: 1.02 per 1 year [1.01-1.03], P<0.001), history of cancer (HR: 3.60 [2.75-4.67], P<0.001), autoimmune disorder (HR: 1.51 [1.09-2.05], P=0.01), and absence of transient provoking risk factors for VTE (HR: 1.36 [1.03-1.80], P=0.03) were independently associated with newly-diagnosed cancer after diagnosis of VTE. Conclusions In the current era, the incidence of newly-diagnosed cancer was 3.7% at 1-year with initial acute increase followed by continuous increase, and several independent risk factors were identified, which might be useful for consideration of optimal screening strategies for occult cancer based on individual risk.Newly-diagnosed cancer
No takes yet. Share an insight, caveat, or question.
Yamashita et al. (2023) conducted an observational in Acute symptomatic venous thromboembolism without known active cancer (n=3,706). Newly-diagnosed cancer after VTE diagnosis (and associated risk factors including history of cancer) vs. No newly-diagnosed cancer after VTE diagnosis was evaluated on Newly-diagnosed cancer and 7-year all-cause death (HR 3.60, 95% CI 2.75-4.67, p=<0.001). Newly-diagnosed cancer after VTE occurred in 3.7% at 1 year (16.0% at 7 years), predicted by prior cancer (HR 3.60; 95% CI 2.75-4.67; P<0.001) and linked to higher 7-year mortality (59.3% vs 21.0%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: